Bluejay aims to develop new treatments for the functional cure of chronic HBV infection
- Focus on reduction of HBs antigen (HBsAg) and restoration of adaptive immunity
- Combination of Bluejay’s two lead product candidates and with approved products (NUC, HBV vaccine) may significantly increase HBV functional cure rates
Programs have highly differentiated first-in-class or best-in-class profiles
- BJT-778, a human anti-HBsAg monoclonal antibody, significantly improved in drug profile over the antibodies under development currently (potency, epitope, safety), best-in-class.
- BJT-754, a small molecule HBsAg inhibitor, is the only current option for an oral curative treatment and is the ideal combination partner, first-in-class.